Last reviewed · How we verify
MEDI-573
At a glance
| Generic name | MEDI-573 |
|---|---|
| Sponsor | MedImmune LLC |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Study of MEDI-573 Plus Standard Endocrine Therapy for Women With Hormone-sensitive Metastatic Breast Cancer (PHASE2)
- A Dose-escalation Study to Evaluate the Safety, Tolerability, and Antitumor Activity of MEDI-573 in Subjects With Advanced Solid Tumors (PHASE1)
- MEDI-573 in Combination With SOC in Unresectable or Metastatic HCC. (PHASE1)
- Dose-escalation Study to Assess Safety, Tolerability and Pharmacokinetics of MEDI-573 in Japanese Subjects (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- MEDI-573 CI brief — competitive landscape report
- MEDI-573 updates RSS · CI watch RSS
- MedImmune LLC portfolio CI